Shannon Thyme Klinger Sells 5,178 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) insider Shannon Thyme Klinger sold 5,178 shares of Moderna stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $148.09, for a total value of $766,810.02. Following the completion of the transaction, the insider now owns 15,947 shares of the company’s stock, valued at $2,361,591.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shannon Thyme Klinger also recently made the following trade(s):

• On Tuesday, May 28th, Shannon Thyme Klinger sold 1,296 shares of Moderna stock. The shares were sold at an average price of $162.47, for a total value of $210,561.12.

Moderna Stock Down 0.1 %

NASDAQ:MRNA traded down $0.20 during trading hours on Tuesday, hitting $148.39. 1,916,207 shares of the stock traded hands, compared to its average volume of 4,224,215. The firm has a 50 day moving average price of $125.52 and a 200 day moving average price of $106.69. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47. The firm has a market cap of $56.87 billion, a price-to-earnings ratio of -9.45 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. During the same period in the previous year, the company posted $0.19 EPS. Moderna’s revenue was down 91.0% on a year-over-year basis. Equities research analysts anticipate that Moderna, Inc. will post -7.46 earnings per share for the current year.

Institutional Investors Weigh In On Moderna

Large investors have recently bought and sold shares of the business. Cedar Wealth Management LLC lifted its position in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the last quarter. Allworth Financial LP grew its stake in shares of Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the last quarter. TIAA Trust National Association grew its stake in shares of Moderna by 2.3% during the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the last quarter. Principle Wealth Partners LLC grew its stake in shares of Moderna by 4.3% during the first quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after purchasing an additional 102 shares during the last quarter. Finally, Sound Income Strategies LLC grew its stake in shares of Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MRNA. HSBC restated a “reduce” rating and issued a $86.00 target price (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer lifted their target price on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Canaccord Genuity Group lifted their target price on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research note on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Finally, UBS Group boosted their price objective on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $128.02.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.